Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04142437




Registration number
NCT04142437
Ethics application status
Date submitted
17/10/2019
Date registered
29/10/2019
Date last updated
10/05/2024

Titles & IDs
Public title
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
Scientific title
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
Secondary ID [1] 0 0
20324
Universal Trial Number (UTN)
Trial acronym
ON-TRK
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion 0 0
Condition category
Condition code

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Drugs - larotrectinib(Vitrakvi, BAY2757556)

GI - adult patients with gastrointestinal (GI) cancer

H&N - adult patients with head and neck (H&N) cancer

STS - adult patients with soft tissue sarcoma (STS)

CNS - adult patients with primary central nervous system (CNS) cancer

Lung - adult patients with lung cancer

Melanoma - adult patients with melanoma

Pediatric - all pediatric patients regardless of tumor type will be enrolled under this cohort

other - patients with other tumor types


Treatment: Drugs: larotrectinib(Vitrakvi, BAY2757556)
In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with treatment-emergent adverse events (TEAEs)
Timepoint [1] 0 0
Up to 30 days after last dose
Primary outcome [2] 0 0
Severity of TEAEs
Timepoint [2] 0 0
Up to 30 days after last dose
Primary outcome [3] 0 0
Seriousness of TEAEs
Timepoint [3] 0 0
Up to 30 days after last dose
Primary outcome [4] 0 0
Outcome of TEAEs
Timepoint [4] 0 0
Up to 30 days after last dose
Primary outcome [5] 0 0
Causality of TEAEs
Timepoint [5] 0 0
Up to 30 days after last dose
Primary outcome [6] 0 0
Action taken related to larotrectinib treatment
Timepoint [6] 0 0
Up to 30 days after last dose
Secondary outcome [1] 0 0
Objective response rate (ORR)
Timepoint [1] 0 0
Up to 8 years
Secondary outcome [2] 0 0
Disease control rate (DCR)
Timepoint [2] 0 0
Up to 8 years
Secondary outcome [3] 0 0
Duration of response (DOR)
Timepoint [3] 0 0
Up to 8 years
Secondary outcome [4] 0 0
Time to response (TTR)
Timepoint [4] 0 0
Up to 8 years
Secondary outcome [5] 0 0
Progression-free survival (PFS)
Timepoint [5] 0 0
Up to 8 years
Secondary outcome [6] 0 0
Overall survival (OS)
Timepoint [6] 0 0
Up to 8 years
Secondary outcome [7] 0 0
Total dose
Timepoint [7] 0 0
Up to 8 years
Secondary outcome [8] 0 0
Starting and ending dose
Timepoint [8] 0 0
Up to 8 years
Secondary outcome [9] 0 0
Dose modification during treatment
Timepoint [9] 0 0
Up to 8 years
Secondary outcome [10] 0 0
Duration of treatment (DOT)
Timepoint [10] 0 0
Up to 8 years
Secondary outcome [11] 0 0
ORR by patient subgroup(s)
Timepoint [11] 0 0
Up to 8 years
Secondary outcome [12] 0 0
DCR by patient subgroup(s)
Timepoint [12] 0 0
Up to 8 years
Secondary outcome [13] 0 0
DOR by patient subgroup(s)
Timepoint [13] 0 0
Up to 8 years
Secondary outcome [14] 0 0
TTR by patient subgroup(s)
Timepoint [14] 0 0
Up to 8 years
Secondary outcome [15] 0 0
PFS by patient subgroup(s)
Timepoint [15] 0 0
Up to 8 years
Secondary outcome [16] 0 0
OS by patient subgroup(s)
Timepoint [16] 0 0
Up to 8 years
Secondary outcome [17] 0 0
Number of patients with change in height and weight from baseline by visit, neurological abnormalities (normal/abnormal)
Timepoint [17] 0 0
Up to 8 years
Secondary outcome [18] 0 0
Number of patients with abnormal developmental milestones
Timepoint [18] 0 0
Up to 8 years
Secondary outcome [19] 0 0
Number of patients with abnormal Tanner stage
Timepoint [19] 0 0
Up to 8 years

Eligibility
Key inclusion criteria
- Adult and pediatric (from 1 month to 18-year-old) patients

- Patients with locally advanced or metastatic solid tumor harboring an NTRK gene
fusion. NTRK (NTRK1, NTRK2, and NTRK3) gene fusions will be identified locally.
Acceptable methods of detection of NTRK gene fusion include NGS, fluorescence in situ
hybridization (FISH), reverse-transcription polymerase chain reaction (rt-PCR) or any
other genomic testing able to detect NTRK gene fusion. If a pan-TRK IHC method is
used, this result needs to be accompanied with the results using one of the other
methods noted above.

- Life expectancy of at least 3 months based on clinical judgement

- Decision to treat with larotrectinib made by the treating physician prior to study
enrollment

- Patients can also be enrolled if the initial visit (larotrectinib start date) occurred
within 2 months ±3 days prior to informed consent signed date

- Signed informed consent form

- For patients under legal age, signed assent by the patient (where applicable) and
parental/legal guardian signed informed consent is required
Minimum age
1 Month
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any contraindications as listed in the local approved product information

- Pregnancy

- Participation in an investigational program with interventions outside of routine
clinical practice

- Prior treatment with larotrectinib or other kinase inhibitor with TRK inhibition

- Patients with NTRK gene amplification or NTRK point mutation

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/04/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/03/2030
Actual
Sample size
Target
300
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Many Locations - Multiple Locations
Recruitment postcode(s) [1] 0 0
- Multiple Locations
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Maine
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Nevada
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
South Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
West Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Multiple Locations
Country [26] 0 0
Austria
State/province [26] 0 0
Multiple Locations
Country [27] 0 0
Belgium
State/province [27] 0 0
Multiple Locations
Country [28] 0 0
Brazil
State/province [28] 0 0
Multiple Locations
Country [29] 0 0
Canada
State/province [29] 0 0
Multiple Locations
Country [30] 0 0
China
State/province [30] 0 0
Multiple Locations
Country [31] 0 0
Denmark
State/province [31] 0 0
Multiple Locations
Country [32] 0 0
Finland
State/province [32] 0 0
Multiple Locations
Country [33] 0 0
France
State/province [33] 0 0
Multiple Locations
Country [34] 0 0
Germany
State/province [34] 0 0
Multiple Locations
Country [35] 0 0
Greece
State/province [35] 0 0
Multiple Locations
Country [36] 0 0
Ireland
State/province [36] 0 0
Multiple Locations
Country [37] 0 0
Italy
State/province [37] 0 0
Multiple Locations
Country [38] 0 0
Japan
State/province [38] 0 0
Multiple Locations
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Multiple Locations
Country [40] 0 0
Luxembourg
State/province [40] 0 0
Multiple Locations
Country [41] 0 0
Norway
State/province [41] 0 0
Multiple Locations
Country [42] 0 0
Russian Federation
State/province [42] 0 0
Multiple Locations
Country [43] 0 0
Singapore
State/province [43] 0 0
Multiple Locations
Country [44] 0 0
Spain
State/province [44] 0 0
Multiple Locations
Country [45] 0 0
Sweden
State/province [45] 0 0
Multiple Locations
Country [46] 0 0
Switzerland
State/province [46] 0 0
Multiple Locations
Country [47] 0 0
Taiwan
State/province [47] 0 0
Multiple Locations
Country [48] 0 0
United Kingdom
State/province [48] 0 0
Multiple Locations

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
In this observational study researcher want to learn more about the effectiveness of drug
VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use
in patients with TRK fusion cancer which is locally advanced or spread from the place where
it started to other places in the body. TRK fusion cancer is a term used to describe a
variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic
Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or
fuses, with a different gene. This joining results in the activation of certain proteins (TRK
fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an
approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult
and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the
decision to treat their disease with VITRAKVI has been made by their treating physicians.
During the study, patients' medical information such as treatment information with VITRAKVI,
other medication or treatments, changes in disease status and other health signs and symptoms
will be collected within the normal medical care by the treating doctor. Participants will be
observed over a period from 24 to 60 months.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04142437
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Bayer Clinical Trials Contact
Address 0 0
Country 0 0
Phone 0 0
(+)1-888-84 22937
Fax 0 0
Email 0 0
clinical-trials-contact@bayer.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04142437